Aislandi - Kiaisilandi - LYFJASTOFNUN (Icelandic Medicines Agency)

sandoz a/s - tacrolimusum mónohýdrat - hart forðahylki - 3 mg

Aislandi - Kiaisilandi - LYFJASTOFNUN (Icelandic Medicines Agency)

astellas pharma a/s* - tacrolimusum mónohýdrat - hart hylki - 0,5 mg

Aislandi - Kiaisilandi - LYFJASTOFNUN (Icelandic Medicines Agency)

astellas pharma a/s* - tacrolimusum mónohýdrat - hart hylki - 1 mg

Aislandi - Kiaisilandi - LYFJASTOFNUN (Icelandic Medicines Agency)

astellas pharma a/s* - tacrolimusum mónohýdrat - hart hylki - 5 mg

Aislandi - Kiaisilandi - LYFJASTOFNUN (Icelandic Medicines Agency)

medical valley invest ab - enalaprilum maleat - tafla - 20/12,5 mg

Aislandi - Kiaisilandi - LYFJASTOFNUN (Icelandic Medicines Agency)

medical valley invest ab - amlodipinum besýlat - tafla - 10 mg

Aislandi - Kiaisilandi - LYFJASTOFNUN (Icelandic Medicines Agency)

medical valley invest ab - amlodipinum besýlat - tafla - 5 mg

Umoja wa Ulaya - Kiaisilandi - EMA (European Medicines Agency)

takeda pharmaceuticals international ag ireland branch - maribavir - cytomegalovirus sýkingar - veirueyðandi lyf til almennrar notkunar - livtencity is indicated for the treatment of cytomegalovirus (cmv) infection and/or disease that are refractory (with or without resistance) to one or more prior therapies, including ganciclovir, valganciclovir, cidofovir or foscarnet in adult patients who have undergone a haematopoietic stem cell transplant (hsct) or solid organ transplant (sot). Íhuga ætti að opinbera leiðsögn á réttri notkun af veirum.

Aislandi - Kiaisilandi - LYFJASTOFNUN (Icelandic Medicines Agency)

krka sverige ab - enalaprilum maleat; hydrochlorothiazidum inn - tafla - 20 mg /12,5 mg

Aislandi - Kiaisilandi - LYFJASTOFNUN (Icelandic Medicines Agency)

krka sverige ab - enalaprilum maleat - tafla - 5 mg